Symbols

GKOS

Glaukos·NYSE

--(--)

GKOS fundamentals

GKOS Q4 2025 Earnings

Glaukos (GKOS) released its earnings on Feb 17, 2026: revenue was 143.12M (YoY +35.66%), beat estimates; EPS was -0.28 (YoY +30.00%), missed estimates.

Revenue / YoY

143.12M

+35.66%

EPS / YoY

-0.28

+30.00%

Report date

Feb 17, 2026

GKOS Earnings Call Summary for Q4,2025

Record Growth: Q4 2025 net sales of $143.1 million (+36% YoY), full-year $507.4 million (+32% YoY), with 2026 guidance of $600-620 million.
iDose Dominance: Q4 iDose sales $45 million, full-year $136 million, with FDA approval for re-administration driving adoption.
Epioxa Breakthrough: FDA-approved topical therapy for keratoconus, set to launch Q2 2026 with 50% U.S. population coverage.
Financial Discipline: 2026 operating expenses ~15% growth, balanced for cash flow breakeven, with focus on iDose and Epioxa investments.

Earnings

EPS

Revenue

Revenue & Expenses

GKOS has released its 2025 Q4 earnings report, with revenue of 143.12M, reflecting a YoY change of 35.66%, and net profit of -133.66M, showing a YoY change of -298.03%. The Sankey diagram below clearly presents GKOS's revenue sources and cost distribution.

Key Indicators

Glaukos (GKOS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Glaukos (GKOS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Glaukos (GKOS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Glaukos (GKOS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown